The presence of idiopathic thrombocytopenic purpura correlates with lower rate of acute ST-elevation myocardial infarction

被引:4
作者
Davis, Mitchell [1 ]
Movahed, Mohammad Reza [1 ,2 ]
Hashemzadeh, Mehrtash [4 ]
Hashemzadeh, Mehrnoosh [1 ,3 ]
机构
[1] Univ Arizona, Coll Med Phoenix, Tucson, AZ 85004 USA
[2] CareMore, Tucson, AZ 85718 USA
[3] Pima Community Coll, Tucson, AZ 85709 USA
[4] Long Beach VA Healthcare Syst, Long Beach, CA USA
关键词
acute coronary syndrome; auto immune thrombocytopenia; idiopathic thrombocytopenic purpura; ITP; myocardial infarction; thrombocytopenic; PERCUTANEOUS CORONARY INTERVENTION; IMMUNE THROMBOCYTOPENIA; PLASMINOGEN-ACTIVATOR; INHIBITION; EPTIFIBATIDE; THROMBOSIS; PLATELETS; ARTERIAL; CHILDREN; ANTIBODY;
D O I
10.2217/fca-2020-0183
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Platelets are important in the pathogenesis of myocardial infarction (MI). We hypothesize that patients with acquired thrombocytopenia such as idiopathic thrombocytopenic purpura (ITP) may have lower MI rate. Materials & method: The Nationwide Inpatient Sample was used for this study. We analyzed the correlation between ST-elevation MI (STEMI) and ITP utilizing ICD-9 codes. Results: STEMI rate was lower in patients with ITP. We found that, in 2002, STEMI occurred in 0.64% of patients with ITP versus 0.89 (p < 0.007) and for 2011 0.30 versus 0.48 (p < 0.005). After adjusting for tobacco use, diabetes, hypertension, hyperlipidemia, gender and age, STEMI rate remained lower in ITP patients. Conclusion: ITP appears to be associated with lower STEMI rate suggesting low platelet count may exert protective effect from STEMI. Lay abstract: Background: Platelets are fragments of cells in our blood that play a role in the development of myocardial infarction (MI) aka heart attack. The association between medical conditions of low platelet number and MI is unknown. In order to answer this question, we analyzed data from a nationwide database to search for any correlation between a common type of MI called "STEMI" and a disease-state with low platelet number, namely idiopathic thrombocytopenic purpura (ITP). We found that the risk of STEMI was significantly reduced in patients with ITP between the years of 2002 and 2011 suggesting that ITP may exert a protective effect from the occurrence of this type of MI.
引用
收藏
页码:1327 / 1333
页数:7
相关论文
共 37 条
[21]   INHIBITION OF GROWTH OF THROMBUS ON FRESH MURAL THROMBUS - TARGETING OPTIMAL THERAPY [J].
MEYER, BJ ;
BADIMON, JJ ;
MAILHAC, A ;
FERNANDEZORTIZ, A ;
CHESEBRO, JH ;
FUSTER, V ;
BADIMON, L .
CIRCULATION, 1994, 90 (05) :2432-2438
[22]   ANTIPLATELET MONOCLONAL F(AB')2 ANTIBODY DIRECTED AGAINST THE PLATELET GPIIB-IIIA RECEPTOR COMPLEX PREVENTS CORONARY-ARTERY THROMBOSIS IN THE CANINE HEART [J].
MICKELSON, JK ;
SIMPSON, PJ ;
LUCCHESI, BR .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1989, 21 (04) :393-405
[23]  
Neskovic AN, 2010, HERZ, V35, P43, DOI 10.1007/s00059-010-3262-1
[24]   The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia [J].
Neunert, Cindy ;
Lim, Wendy ;
Crowther, Mark ;
Cohen, Alan ;
Solberg, Lawrence, Jr. ;
Crowther, Mark A. .
BLOOD, 2011, 117 (16) :4190-4207
[25]   Management of newly diagnosed immune thrombocytopenia: can we change outcomes? [J].
Neunert, Cindy E. .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2017, :400-405
[26]   Primary coronary intervention for acute ST-elevation myocardial infarction in a patient with immune thrombocytopenic purpura [J].
Nurkalem, Zekeriya ;
Isik, Turgay ;
Cinar, Tufan ;
Ergelen, Mehmet .
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2011, 39 (05) :414-417
[27]   Antiplatelet therapy in acute coronary syndromes: The emergency physician's perspective [J].
Pollack, Charles V., Jr. ;
Hollander, Judd E. .
JOURNAL OF EMERGENCY MEDICINE, 2008, 35 (01) :5-13
[28]   International consensus report on the investigation and management of primary immune thrombocytopenia [J].
Provan, Drew ;
Stasi, Roberto ;
Newland, Adrian C. ;
Blanchette, Victor S. ;
Bolton-Maggs, Paula ;
Bussel, James B. ;
Chong, Beng H. ;
Cines, Douglas B. ;
Gernsheimer, Terry B. ;
Godeau, Bertrand ;
Grainger, John ;
Greer, Ian ;
Hunt, Beverley J. ;
Imbach, Paul A. ;
Lyons, Gordon ;
McMillan, Robert ;
Rodeghiero, Francesco ;
Sanz, Miguel A. ;
Tarantino, Michael ;
Watson, Shirley ;
Young, Joan ;
Kuter, David J. .
BLOOD, 2010, 115 (02) :168-186
[29]   Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction [J].
Racine, E .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (21) :S27-S36
[30]   Glycoprotein IIb-IIIa receptor inhibition with eptifibatide in percutaneous intervention for symptomatic peripheral vascular disease: The CIRCULATE pilot trial [J].
Rocha-Singh, KJ ;
Rutherford, J .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2005, 66 (04) :470-473